is there an emerging epidemic of papilloma virus associated cancers 2. cancer prevention protocol

1
16. IS THERE AN EMERGING EPIDEMIC OF PAPILLOHA VIRUS ASSOCIATED CANCERS. 2. CANCER PREVENTION PROTOCOL. Math6 0.. Battista C., Busutil I#., Hagipantelli R., Cartier I ., Hill M., Billova J., Vovan M.L. Service des Maladies Sanguines et Tumorales L I.C.I.G. (Univ. Paris Sud, CNRS UA 04-1163, Assoc. Cl. Bernard 8 ARC), Hopital Paul-Brousse, 94804 Villejuif, France. Wehave in a first abstract described OUK investigation protocol. The treatmentprotocolcomprises: firstthetreatmentof associated other STD; second the systemic administration (phase II study) of retard- D-Trp-6-LH-RH. Third in case of non complete regression, the laser treatment or fluoro-uracil local application according to the presentation of the lesions. Fourth a randomized trial with local retinoid (tetrinoine) is conducted. Fifth a local application of 8 interferon is made if viroids are found at EM after the above treatments. Then a systemic and local immunologic treatment with bestatine and zinc is conducted, the indications and effect evaluation are determined by CD4, CD8, NK and macrophage cell evaluation.

Upload: phunglien

Post on 31-Dec-2016

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Is there an emerging epidemic of papilloma virus associated cancers 2. Cancer prevention protocol

16. IS THERE AN EMERGING EPIDEMIC OF PAPILLOHA VIRUS ASSOCIATED

CANCERS.

2. CANCER PREVENTION PROTOCOL.

Math6 0.. Battista C., Busutil I#., Hagipantelli R., Cartier

I ., Hill M., Billova J., Vovan M.L.

Service des Maladies Sanguines et Tumorales L I.C.I.G. (Univ.

Paris Sud, CNRS UA 04-1163, Assoc. Cl. Bernard 8 ARC),

Hopital Paul-Brousse, 94804 Villejuif, France.

Wehave in a first abstract described OUK investigation protocol. The

treatmentprotocolcomprises: firstthetreatmentof associated other

STD; second the systemic administration (phase II study) of retard-

D-Trp-6-LH-RH. Third in case of non complete regression, the laser

treatment or fluoro-uracil local application according to the

presentation of the lesions. Fourth a randomized trial with local

retinoid (tetrinoine) is conducted. Fifth a local application of 8

interferon is made if viroids are found at EM after the above

treatments. Then a systemic and local immunologic treatment with

bestatine and zinc is conducted, the indications and effect

evaluation are determined by CD4, CD8, NK and macrophage cell

evaluation.